Overview
- A University of Pennsylvania analysis of more than 111,000 overweight or obese women published in JCO Oncology Practice and presented at ASCO found that patients with prescriptions for GLP‑1 receptor agonists had roughly 30–35% lower breast cancer incidence compared with non‑users.
- The Penn result adds to several large retrospective studies, including a VCU analysis reported in JAMA Network Open and multiple ASCO presentations that showed similar roughly 30% reductions and signals of better cancer outcomes among GLP‑1 users.
- Researchers caution the findings are observational and do not prove causation because the studies lack details on specific drug, dose, duration and adherence, do not account for genetic risk or cancer stage, and may misclassify users who obtained drugs outside the health system.
- Penn investigators are now seeking funding for a multisite randomized clinical trial, planned as a five‑year study, to test whether GLP‑1s actually prevent new breast cancers or reduce recurrence and to define which patients, agents and treatment lengths might benefit.
- If trials confirm benefit the consequences would be wide ranging for patients and policy: clinicians would need safety monitoring and guidance, payers would face cost and eligibility decisions, and researchers would probe mechanisms such as weight loss, reduced inflammation and altered insulin signaling.